Neuroscience Archives - Page 6 of 6

Pfizer Launches New “Moodivator” App to Help Support, Encourage and Motivate People with Depression

Apps, Business, Depression, Major Depressive Disorder, Mental Health Disorders, Product Launches

Pfizer Inc. announced it has launched a new app, Moodivator, to help motivate and encourage the millions of adults who experience depression.

September 13, 2016/by Administrator

Med Ad News’ first edition of the Pharma Leaders of Innovation special feature showcases two CEOs focusing outside the big pharma box and an agency tech leader.

August 17, 2016/by Christiane Truelove

ZEMBRACE SymTouch now commercially available in the U.S.

5-HT1B/ID receptor agonist, Launches, Migraine, Migraine, Product Launches, Therapeutics

Hyderabad, India and Princeton, NJ, USA. April 19, 2016 — Promius Pharma LLC, a subsidiary of Dr. Reddy’s Laboratories, announced today that ZEMBRACE SymTouch is now commercially available in the […]

April 19, 2016/by Administrator

2016 Annual Report: Top 10 Pipelines

"Bad" LDL Cholesterol, Alzheimer's Diseases, Approvals, Big Pharma, Biologics License Application (BLA), Biosimilars, Biotech, Biotech/Biopharma, Biotechnology, Bispecific CD19-directed CD3 T cell engager (BiTE) antibodies, Blockbusters, Blood Cancers, Breakthrough Designation, Breakthrough Therapy, Breakthrough Therapy Designation, Breakthrough Therapy Designation, Cells, Chimeric Antigen Receptor T Cell Therapy (CART), Cholesterol, Chronic Lymphocytic Leukemia, Clinical Trials, Collaboration, Collaborations, Collaborations, Cystic Fibrosis, Deals, Diabetes, DNA, EGFR Inhibitors, Europe, European Commission, FDA, FDA/Regulatory, February 2016, Glucagon-Like Peptide-1 (GLP-1) Analogs, Immune Response, Immune System, Immune Systems, Immunotherapies, Influenza, Inhalers, Issue Archives, Mantle Cell Lymphoma (MCL), Monoclonal Antibodies, Multiple Myeloma, NDA, Neuroscience, New Drug Application (NDA), New Molecular Entities, Non-Small Cell Lung Cancer, Oncology, Pain, Parkinson's, Parkinson's Disease, Plaque Psoriasis, Potential Blockbusters, Psoriasis, R&D, Sales, SGLT2 Inhibitors, Special Reports, Specialty Therapy, Technology, TGF-Beta Inhibitors, The New England Journal of Medicine (NEJM), Therapeutics, Top 10 Pipelines, Transforming Growth Factor-beta (TGFb), Type 1 Diabetes, Type 2 Diabetes, Vaccines, Waldenstrom’s macroglobulinemia

The pharma industry’s R&D concentration has been shifting towards specialty therapy areas as research and development returns decline for some leaders.

February 10, 2016/by Andrew Humphreys

Aurobindo Receives FDA Approval for Memantine Hydrochloride Tablets USP, 5 mg and 10 mg

Abbreviated New Drug Applications (ANDAs), Alzheimer's, Alzheimer's Diseases, ANDAs, FDA, FDA/Regulatory, Generics

Dayton, N.J., October 22, 2015 – Aurobindo Pharma Limited has received final approval from the U.S. Food and Drug Administration for Memantine Hydrochloride Tablets USP, 5 mg and 10 mg. […]

October 22, 2015/by Administrator